Litigation Details for Ferring Pharmaceuticals Inc. v. Novel Laboratories, Inc. (D. Del. 2017)

Ferring Pharmaceuticals Inc. v. Novel Laboratories, Inc. (D. Del. 2017)

Docket		Date Filed	2017-07-05
Court	District Court, D. Delaware	Date Terminated	2019-02-01
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,450,338; 8,481,083
Link to Docket	External link to docket

Details for Ferring Pharmaceuticals Inc. v. Novel Laboratories, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-07-05				External link to document
2017-07-05	128		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,450,338; US 8,481,083; US…2017 1 February 2019 1:17-cv-00894 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-07-05	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,450,338; US 8,481,083; US…2017 1 February 2019 1:17-cv-00894 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Ferring Pharmaceuticals v. Novel Laboratories: Apriso Patent Litigation Summary and Analysis

Last updated: August 25, 2026

Ferring Pharmaceuticals Inc. v. Novel Laboratories, Inc., No. 1:17-cv-00894, was an Abbreviated New Drug Application (ANDA) patent case in the U.S. District Court for the District of Delaware concerning Novel’s proposed generic version of Apriso, Ferring’s extended-release mesalamine product. The case was filed under the Hatch-Waxman Act after Novel submitted an ANDA containing Paragraph IV certifications against Ferring’s listed patents. The litigation focused on patent protection for mesalamine delivery technology, rather than the chemical identity of mesalamine itself.

The public docket reflects a conventional ANDA dispute that ended without a reported trial judgment establishing infringement or invalidity. The parties resolved the action through a negotiated disposition, and the case was closed. The publicly available record does not provide a merits ruling that would support a definitive conclusion that the asserted patents were valid, infringed, or enforceable. (U.S. District Court for the District of Delaware, 2017)

What drug and ANDA were involved in Ferring v. Novel?

The litigation concerned Apriso, a prescription mesalamine product approved for the maintenance of remission of ulcerative colitis in adults. Apriso contains mesalamine in extended-release capsules designed to release the active ingredient in the colon. Ferring markets Apriso under NDA No. 022372. (U.S. Food and Drug Administration, 2013)

Item	Detail
Brand	Apriso
Active ingredient	Mesalamine
Dosage form	Extended-release capsules
Strength	0.375 g per capsule
Therapeutic area	Ulcerative colitis
Regulatory pathway	NDA
NDA holder	Ferring Pharmaceuticals
Generic pathway	ANDA
Defendant	Novel Laboratories, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-00894
Filing year	2017

The commercial issue was whether Novel could obtain FDA approval and launch generic mesalamine extended-release capsules before expiration of Ferring’s patent rights.

What patents protected Apriso in the Novel litigation?

Apriso’s patent protection derived from patents covering the formulation and release characteristics of mesalamine. The asserted rights were directed to the dosage form and delivery system, including controlled release of mesalamine to the gastrointestinal tract.

The litigation did not concern a simple formulation of mesalamine. Mesalamine has been used for decades, and the principal patent value in Apriso was associated with the product’s release profile, excipient architecture, capsule design, and ability to deliver mesalamine to the colon.

Public patent records identify Ferring-associated mesalamine formulation patents, including U.S. Patent No. 6,773,720 and later patents directed to controlled-release oral pharmaceutical compositions. The relevant Orange Book listing and the complaint should be read together because not every Ferring patent relating to mesalamine necessarily formed part of the Novel case. (U.S. Patent and Trademark Office, n.d.; U.S. Food and Drug Administration, 2024)

Why formulation patents mattered

A generic applicant can avoid infringement by using a materially different formulation or release mechanism. That makes formulation litigation more technically complex than a case involving a single active-ingredient patent.

For Apriso, the critical questions included:

1. Whether Novel’s proposed capsule contained the claimed formulation components.
2. Whether the generic product produced the claimed release profile.
3. Whether the claims required particular coating, matrix, pH-dependent, or gastrointestinal-release properties.
4. Whether the asserted claims were anticipated or obvious in view of earlier mesalamine formulations.
5. Whether the claims were sufficiently definite and enabled across their full scope.

The commercial value of the patents therefore depended on claim scope and the FDA-approved product design, not simply on the remaining life of mesalamine-related patents.

When did Novel file its Paragraph IV challenge?

Novel’s ANDA submission triggered a Paragraph IV dispute. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Under the Hatch-Waxman framework, the certification is treated as an artificial act of infringement, allowing the patent holder to sue before commercial launch. (21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2))

Ferring filed the action in 2017, within the statutory window following notification of Novel’s Paragraph IV certification. The filing imposed the automatic 30-month stay on FDA approval of the ANDA, subject to earlier termination through court action, settlement, or other statutory events.

The public case record does not establish that Novel launched its product during the pendency of the litigation. The absence of a reported launch is consistent with the normal effect of the 30-month stay and the commercial leverage held by the branded sponsor during settlement negotiations.

What was the litigation timeline?

Date or period	Event
2017	Novel submitted an ANDA for generic Apriso and provided Paragraph IV notice.
2017	Ferring filed patent infringement litigation in the District of Delaware.
2017-2018	The parties litigated the ANDA claims and related procedural issues.
Subsequent period	The action was resolved without a publicly reported trial verdict.
Final docket disposition	The case was closed following negotiated resolution.

The docket does not report a Federal Circuit decision or a substantive district-court judgment invalidating the asserted patents. The case therefore has limited precedential value on the technical merits of Apriso’s formulation claims.

Did Novel win or lose the Apriso patent case?

Neither party received a publicly reported merits victory. The case ended through negotiated resolution rather than a published judgment after trial.

That distinction matters for portfolio analysis:

• Ferring did not obtain a reported judicial finding confirming infringement.
• Novel did not obtain a reported judicial finding that the patents were invalid or unenforceable.
• The settlement preserved confidentiality over key commercial terms.
• The resolution reduced immediate litigation risk for both parties.
• Any authorized generic entry date, royalty structure, or launch restriction cannot be inferred reliably from the public docket alone.

A Hatch-Waxman settlement can produce a generic entry date that is earlier than patent expiration without creating a public invalidity ruling. The settlement can also include a license, supply arrangement, or other commercial provisions. None of those mechanisms necessarily indicates that the branded patent estate was weak.

What was the Orange Book status of Apriso?

Apriso’s Orange Book status was based on patents submitted by the NDA holder and associated with the approved product. Orange Book listings are important because they determine which patents an ANDA applicant must address through a certification.

The Orange Book distinguishes between:

• Patents claiming the drug substance.
• Patents claiming the drug product or formulation.
• Method-of-use patents.
• Patents that may be subject to a patent-use code.
• Regulatory exclusivity periods separate from patent expiration.

Apriso’s relevant protection was primarily formulation-based. The Orange Book listing did not give Ferring perpetual protection over mesalamine. It gave Ferring a statutory mechanism to challenge a generic applicant whose ANDA product allegedly practiced the listed claims. (U.S. Food and Drug Administration, 2024)

A listed patent can also be vulnerable to an ANDA applicant’s noninfringement position. If the generic applicant designs around a release limitation, changes excipients, or uses a different coating system, the Paragraph IV case may turn on claim construction and product testing rather than on a direct comparison of active ingredients.

Did Apriso have method-of-use patent protection?

Method-of-use rights were less central than formulation rights in this dispute. Apriso is approved for maintenance of remission in ulcerative colitis, but a method-of-use patent only creates a substantial regulatory barrier when the patent is properly listed with an applicable use code and the generic labeling raises infringement concerns.

A generic applicant may use a section viii statement to carve out a patented indication from its labeling when permitted by the FDA. That pathway is less effective against formulation claims because a formulation patent generally covers the product itself, regardless of the indication for which it is prescribed.

The principal risk for Novel was therefore the physical composition and release design of the proposed generic capsule.

How strong was Ferring’s Apriso patent estate?

Ferring’s estate had moderate strategic strength but did not present the same barrier as a live compound patent.

Factors supporting Ferring

• Apriso used a differentiated extended-release delivery system.
• The formulation claims could reach competing products even though mesalamine itself was no longer new.
• ANDA litigation delayed approval through the statutory 30-month stay.
• Product-specific formulation testing can make early design-around difficult.
• The brand had an established FDA-approved product and commercial market.

Factors supporting Novel

• Mesalamine was a mature active ingredient with extensive prior art.
• Formulation claims are often vulnerable to obviousness attacks based on known coatings, excipients, and release technologies.
• A generic applicant can potentially avoid infringement by modifying the delivery system.
• The value of the estate declined as patent expiry approached.
• Product-specific claims may be narrow if they depend on detailed physical or dissolution characteristics.

The absence of a reported merits judgment means the case cannot be scored solely from the disposition. Settlement is compatible with a strong patent position, a weak patent position, or a commercial decision to avoid litigation cost.

What generic entry risks existed for Apriso?

The main generic-entry scenarios were:

Scenario	Effect on Ferring
Patent-validity victory for Ferring	Delayed generic approval until patent expiration or licensed entry.
Novel noninfringement victory	Potential early generic approval and launch.
Invalidity victory for Novel	Loss of the relevant patent barrier before expiration.
Settlement with licensed entry	Managed erosion on a negotiated date.
Regulatory delay unrelated to patents	Patent protection could remain intact while approval timing moved.
Multiple ANDA filers	Increased probability of price erosion and accelerated market entry.

The highest-value risk was not loss of exclusivity for mesalamine as a molecule. It was loss of exclusivity for the Apriso release platform. A successful generic challenge to the formulation patents could have allowed substitution without waiting for all branded product patents to expire.

What was the commercial impact of the litigation?

Apriso was one component of Ferring’s gastrointestinal portfolio. Generic entry would be expected to pressure:

• Apriso prescription volume.
• Net price and rebate levels.
• Pharmacy substitution rates.
• Formulary positioning.
• Physician retention where a generic was therapeutically substitutable.
• Ferring’s ability to defend market share through product differentiation.

The public record does not provide a reliable case-specific revenue figure attributable to Apriso or a disclosed settlement payment. Revenue exposure should therefore be modeled from Apriso sales, the expected generic discount, the number of potential ANDA entrants, and the negotiated entry date rather than from the docket disposition alone.

What licensing or settlement agreement resolved the case?

The case was resolved without a publicly reported merits decision. The public docket does not disclose a complete set of settlement terms sufficient to determine:

• The authorized generic launch date.
• Whether Novel received a license.
• Whether Ferring agreed to a supply arrangement.
• Whether royalties were payable.
• Whether the settlement included restrictions on future products.
• Whether the agreement was reviewed under the FTC’s pharmaceutical settlement reporting framework.

Confidential Hatch-Waxman settlements are common. A docket closure should not be characterized as a finding that the patent estate was invalid or that Novel’s product was noninfringing.

What is the current litigation significance of Ferring v. Novel?

The case is most useful as evidence of Ferring’s enforcement strategy for Apriso formulation patents and of the commercial importance of release technology in generic mesalamine disputes. It is not a controlling precedent on claim construction, obviousness, enablement, or infringement because no reported merits opinion appears to have resulted from the case.

For diligence purposes, the case should be read with:

• Apriso’s current FDA label.
• The current Orange Book listing.
• Patent prosecution histories.
• Any later ANDA litigation involving mesalamine extended-release products.
• FDA approval records for competing products.
• Public FTC settlement reports, where available.

Key Takeaways

• Ferring v. Novel, No. 1:17-cv-00894, concerned generic Apriso, an extended-release mesalamine product.
• Novel’s ANDA included Paragraph IV certifications, prompting Ferring’s 2017 Hatch-Waxman suit.
• The dispute centered on formulation and controlled-release technology, not mesalamine as a new chemical entity.
• The case ended without a reported trial judgment or appellate merits decision.
• Public materials do not establish whether Novel’s proposed product infringed or whether Ferring’s asserted claims would have survived invalidity challenges.
• The settlement terms, including any authorized generic entry date, were not fully disclosed in the public docket.
• Generic-entry risk was driven by the durability of Ferring’s formulation claims and the possibility of a design-around product.
• The case has limited precedential value but remains relevant to Apriso exclusivity, Orange Book strategy, and generic-launch analysis.

FAQs About Ferring v. Novel Laboratories

Was Ferring v. Novel a biologic or biosimilar case?

No. The case involved a small-molecule mesalamine product and an ANDA, not a biologic license application or biosimilar application.

Did Novel challenge the mesalamine molecule itself?

The dispute primarily concerned Apriso’s extended-release formulation and delivery characteristics. Mesalamine itself was a mature active ingredient.

Did the case create binding precedent?

No reported merits opinion from the case created binding appellate precedent on Apriso’s formulation patents.

Could a generic manufacturer avoid Apriso patents through a formulation change?

Potentially. A noninfringing design-around could change the release mechanism, excipients, coating, capsule architecture, or other claimed characteristics, subject to FDA requirements and the scope of the asserted claims.

Does the settlement prove that Ferring’s patents were weak?

No. A settlement does not determine patent validity or infringement. It reflects a negotiated allocation of litigation and commercial risk.

References

U.S. District Court for the District of Delaware. (2017). Ferring Pharmaceuticals Inc. v. Novel Laboratories, Inc., No. 1:17-cv-00894.

U.S. Food and Drug Administration. (2013). Apriso (mesalamine) extended-release capsules: Prescribing information. Drugs@FDA.

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

U.S. Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent No. 6,773,720 and related mesalamine formulation patents.

United States Code. (2023). 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).